BBA
GEVA

Baker Bros. Advisors’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Baker Bros. Advisors’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-11,660,432
Closed -$1.14B – 135
2015
Q1 		$1.14B Buy
11,660,432
+1,000,000
+9% +$106M 9.46% 3
2014
Q4 		$989M Hold
10,660,432
– – 10.1% 3
2014
Q3 		$733M Hold
10,660,432
– – 9.23% 4
2014
Q2 		$1.12B Buy
10,660,432
+12,250
+0.1% +$1.04M 13.68% 1
2014
Q1 		$883M Buy
10,648,182
+375,000
+4% +$34.7M 11.23% 2
2013
Q4 		$665M Hold
10,273,182
– – 9.37% 4
2013
Q3 		$651M Buy
10,273,182
+1,050,000
+11% +$51.7M 9.26% 4
2013
Q2 		$387M Buy
+9,223,182
New +$420M 7.66% 5

Baker Bros. Advisors's GEVA Position: Q2 2015 in Review

Baker Bros. Advisors sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 11,660,432 shares — an estimated $1.14B sold.

Baker Bros. Advisors first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $1.14B in Q1 2015. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • Baker Bros. Advisors reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Baker Bros. Advisors sold 11,660,432 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $1.14B.
  • Baker Bros. Advisors first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • Baker Bros. Advisors's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $1.14B in Q1 2015.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Baker Bros. Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.